Intensified Processing for Biopharmaceutical Manufacturing
Technologies That Enable Continuous Production Throughout the Process
Continuous processing in biomanufacturing has the potential to increase production capacity, reduce costs and improve biopharmaceutical product quality. Sartorius Stedim Biotech is collaborating with leading biopharmaceutical companies as they intensify their bioprocesses. With these experiences, we are supporting clients seeking to implement continuous manufacturing operations within their facilities through the provision of technologies, services, insight and expertise.
Single-Use and Intensified Processing in Commercial Biomanufacturing
BPI TV interviews, Biotech Week 2018, Boston, MA: Miriam Monge and Gerben Zijlstra, Sartorius Stedim Biotech, in discussion with Dan Stanton, Editor of Bioprocess Insider
Intensified Upstream Processing
Process Analytical Technologies (PAT) can play an important role in enabling continuous bioprocessing. They help maintain these processes within a steady state. Authors from Sartorius discuss some of the challenges the industry faces in implementing continuous biomanufacturing and how we are addressing them with PAT tools such as the BioPAT® Viamass and the BioPAT® SIMCA-online in the following article: View Publication
Accelerating Intensified Bioprocesses with High-Throughput Small-Scale Tools
In this special report by Sartorius Stedim Biotech in association with BioProcess International the authors illustrate how hybrid continuous processes benefit from single-use technologies. Download now and read how perfusion cell culture can reduce cost and accelerate time-to-market!
Cell Retention Technology
The kSep® centrifuge is a patented, highly versatile technology from Sartorius that biomanufacturers can use for either the optimized harvesting of cell culture supernatant or, alternatively, viable cells. Engineers use the technology for cell retention during intensified cell cultures for recombinant protein production, the removal of cells or micro-carriers during vaccine production or the harvesting of cells during cell and gene therapy manufacturing.
Inside the chambers of the kSep®, cells are maintained within a fluidized bed that is established through the balance of centrifugal and liquid flow forces preventing cell damage and host cell protein release. The fluidized bed allows soluble products to be separated easily from cells with a short, low-volume wash to maximize recovery. When harvesting viable cells, the settings of the kSep® can be adapted to remove dead cells and debris from viable cells in the fluidized bed. The resultant high viablility culture can either be harvested, returned to the same bioreactor or even be used to inoculate a new bioreactor, depending on the application.